Literature DB >> 24256948

Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.

Maria A T Groves, Lily Amanuel, Jamie I Campbell, D Gareth Rees, Sudharsan Sridharan, Donna K Finch, David C Lowe, Tristan J Vaughan.   

Abstract

In vitro selection technologies are an important means of affinity maturing antibodies to generate the optimal therapeutic profile for a particular disease target. Here, we describe the isolation of a parent antibody, KENB061 using phage display and solution phase selections with soluble biotinylated human IL-1R1. KENB061 was affinity matured using phage display and targeted mutagenesis of VH and VL CDR3 using NNS randomization. Affinity matured VHCDR3 and VLCDR3 library blocks were recombined and selected using phage and ribosome display protocol. A direct comparison of the phage and ribosome display antibodies generated was made to determine their functional characteristics.In our analyses, we observed distinct differences in the pattern of beneficial mutations in antibodies derived from phage and ribosome display selections, and discovered the lead antibody Jedi067 had a ~3700-fold improvement in KD over the parent KENB061. We constructed a homology model of the Fv region of Jedi067 to map the specific positions where mutations occurred in the CDR3 loops. For VL CDR3, positions 94 to 97 carry greater diversity in the ribosome display variants compared with the phage display. The positions 95a, 95b and 96 of VLCDR3 form part of the interface with VH in this model. The model shows that positions 96, 98, 100e, 100f, 100 g, 100h, 100i and 101 of the VHCDR3 include residues at the VH and VL interface. Importantly, Leu96 and Tyr98 are conserved at the interface positions in both phage and ribosome display indicating their importance in maintaining the VH-VL interface. For antibodies derived from ribosome display, there is significant diversity at residues 100a to 100f of the VH CDR3 compared with phage display. A unique deletion of isoleucine at position 102 of the lead candidate, Jedi067, also occurs in the VHCDR3.As anticipated, recombining the mutations via ribosome display led to a greater structural diversity, particularly in the heavy chain CDR3, which in turn led to antibodies with improved potencies. For this particular analysis, we also found that VH-VL interface positions provided a source of structural diversity for those derived from the ribosome display selections. This greater diversity is a likely consequence of the presence of a larger pool of recombinants in the ribosome display system, or the evolutionary capacity of ribosome display, but may also reflect differential selection of antibodies in the two systems.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24256948      PMCID: PMC3929446          DOI: 10.4161/mabs.27261

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  29 in total

Review 1.  In vitro selection and evolution of proteins.

Authors:  A Plückthun; C Schaffitzel; J Hanes; L Jermutus
Journal:  Adv Protein Chem       Date:  2000

2.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Improving biosensor analysis.

Authors:  D G Myszka
Journal:  J Mol Recognit       Date:  1999 Sep-Oct       Impact factor: 2.137

4.  Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins.

Authors:  H Mach; C R Middaugh; R V Lewis
Journal:  Anal Biochem       Date:  1992-01       Impact factor: 3.365

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily.

Authors:  J E Sims; C J March; D Cosman; M B Widmer; H R MacDonald; C J McMahan; C E Grubin; J M Wignall; J L Jackson; S M Call
Journal:  Science       Date:  1988-07-29       Impact factor: 47.728

7.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.

Authors:  D J Dripps; B J Brandhuber; R C Thompson; S P Eisenberg
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

8.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

Authors:  R E Hawkins; S J Russell; G Winter
Journal:  J Mol Biol       Date:  1992-08-05       Impact factor: 5.469

Review 9.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

10.  Identification of potent human anti-IL-1RI antagonist antibodies.

Authors:  Zoey L Fredericks; Carla Forte; Irene V Capuano; Hongxing Zhou; Tim Vanden Bos; Paul Carter
Journal:  Protein Eng Des Sel       Date:  2004-01       Impact factor: 1.650

View more
  7 in total

1.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

2.  A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting.

Authors:  Amelie Vallet-Courbin; Mélusine Larivière; Agnès Hocquellet; Audrey Hemadou; Sarjapura-Nagaraja Parimala; Jeanny Laroche-Traineau; Xavier Santarelli; Gisèle Clofent-Sanchez; Marie-Josée Jacobin-Valat; Abdelmajid Noubhani
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

3.  Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation.

Authors:  Denice T Y Chan; Lesley Jenkinson; Stuart W Haynes; Mark Austin; Agata Diamandakis; Daniel Burschowsky; Chitra Seewooruthun; Alexandra Addyman; Sebastian Fiedler; Stephanie Ryman; Jessica Whitehouse; Louise H Slater; Ellen Gowans; Yoko Shibata; Michelle Barnard; Robert W Wilkinson; Tristan J Vaughan; Sarah V Holt; Vincenzo Cerundolo; Mark D Carr; Maria A T Groves
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-02       Impact factor: 11.205

Review 4.  Ribosome Display Technology: Applications in Disease Diagnosis and Control.

Authors:  Adinarayana Kunamneni; Christian Ogaugwu; Steven Bradfute; Ravi Durvasula
Journal:  Antibodies (Basel)       Date:  2020-06-27

5.  Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.

Authors:  Taichi Kuramochi; Siok Wan Gan; Adrian W S Ho; Bei Wang; Nagisa Kageji; Takeru Nambu; Sayaka Iida; Momoko Okuda-Miura; Wei Shan Chia; Chiew Ying Yeo; Dan Chen; Wen-Hsin Lee; Eve Zi Xian Ngoh; Siti Nazihah Mohd Salleh; Cheng-I Wang; Tomoyuki Igawa; Hideaki Shimada
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

Review 6.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12

7.  Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies.

Authors:  Denice T Y Chan; Maria A T Groves
Journal:  Emerg Top Life Sci       Date:  2021-11-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.